Correlation Between Cidara Therapeutics and Spero Therapeutics

Can any of the company-specific risk be diversified away by investing in both Cidara Therapeutics and Spero Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Cidara Therapeutics and Spero Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Cidara Therapeutics and Spero Therapeutics, you can compare the effects of market volatilities on Cidara Therapeutics and Spero Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Cidara Therapeutics with a short position of Spero Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Cidara Therapeutics and Spero Therapeutics.

Diversification Opportunities for Cidara Therapeutics and Spero Therapeutics

-0.79

Correlation Coefficient

Cidara Therapeutics  Spero Therapeutics

Pay attention - limited upside

The 3 months correlation between Cidara and Spero is -0.79. Overlapping area represents the amount of risk that can be diversified away by holding Cidara Therapeutics and Spero Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Spero Therapeutics and Cidara Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Cidara Therapeutics are associated (or correlated) with Spero Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Spero Therapeutics has no effect on the direction of Cidara Therapeutics i.e., Cidara Therapeutics and Spero Therapeutics go up and down completely randomly.

Pair Corralation between Cidara Therapeutics and Spero Therapeutics

Given the investment horizon of 90 days Cidara Therapeutics is expected to under-perform the Spero Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Cidara Therapeutics is 1.06 times less risky than Spero Therapeutics. The stock trades about -0.07 of its potential returns per unit of risk. The Spero Therapeutics is currently generating about 0.01 of returns per unit of risk over similar time horizon. If you would invest  92.00  in Spero Therapeutics on October 22, 2024 and sell it today you would lose (1.00) from holding Spero Therapeutics or give up 1.09% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Cidara Therapeutics  vs.  Spero Therapeutics

Cidara Therapeutics

Risk-Adjusted Performance

16 of 100

Solid

Compared to the overall equity markets, risk-adjusted returns on investments in Cidara Therapeutics are ranked lower than 16 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Cidara Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point.

Spero Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Spero Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Cidara Therapeutics and Spero Therapeutics

The main advantage of trading using opposite Cidara Therapeutics and Spero Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Cidara Therapeutics position performs unexpectedly, Spero Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Spero Therapeutics will offset losses from the drop in Spero Therapeutics' long position.

The idea behind Cidara Therapeutics and Spero Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Volatility Analysis module to get historical volatility and risk analysis based on latest market data.